SCHEMBL2807061

SCHEMBL2807061

O=C(O)CCC(=O)NCCCCCCNC(=O)CCC(=O)O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRMT1 Q99873 1/20 0.60
CASP2 P42575 1/20 0.56
ADRA1A P35348 1/20 0.56
ALDH1A1 P00352 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
EPHX2 P34913 3/20 0.53
NAAA Q02083 1/20 0.52
KDM4E B2RXH2 2/20 0.50
KDM5C P41229 2/20 0.50
PHF8 Q9UPP1 2/20 0.50
KDM2A Q9Y2K7 2/20 0.50
LMNA P02545 1/20 0.50
TSHR P16473 1/20 0.50
KDM6B O15054 1/20 0.50
FOLH1 Q04609 1/20 0.50
EGLN1 Q9GZT9 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.48
MAPK1 P28482 1/20 0.48
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6812011 0.97 PRMT1 (0.56) PRMT1CASP2ADRA1AALDH1A1SMN1; SMN2
SCHEMBL2808393 0.95 PRMT1 (0.68) PRMT1CASP2ADRA1AALDH1A1SMN1; SMN2
SCHEMBL27262151 0.95 PRMT1 (0.68) PRMT1CASP2ADRA1AALDH1A1SMN1; SMN2
SCHEMBL13962790 0.92 KDM4E (0.52) PRMT1CASP2ADRA1AEPHX2KDM4E
SCHEMBL14785655 0.91 PRMT1 (0.52) PRMT1CASP2ADRA1AALDH1A1SMN1; SMN2
SCHEMBL14785620 0.91 PRMT1 (0.52) PRMT1CASP2ADRA1AALDH1A1SMN1; SMN2
SCHEMBL14785612 0.91 PRMT1 (0.52) PRMT1CASP2ADRA1AALDH1A1SMN1; SMN2
SCHEMBL10432996 0.91 PRMT1 (0.52) PRMT1CASP2ADRA1AALDH1A1SMN1; SMN2
SCHEMBL14785733 0.91 PRMT1 (0.52) PRMT1CASP2ADRA1AALDH1A1SMN1; SMN2
SCHEMBL14785685 0.91 PRMT1 (0.52) PRMT1CASP2ADRA1AALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8968711-B2 Cosmetic or dermatological composition comprising a polymer bearing junction groups, and cosmetic treatment process L'OREAL (FR) 2015-03-03 US claimed
US-20100272660-A1 COSMETIC OR PHARMACEUTICAL COMPOSITION COMPRISING A POLYCONDENSATE, THE SAID POLYCONDENSATE AND METHOD OF COSMETIC TREATMENT L'OREAL (FR) 2010-10-28 US claimed
US-20100239509-A1 COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A POLYMER BEARING JUNCTION GROUPS, AND COSMETIC TREATMENT PROCESS L'OREAL (FR) 2010-09-23 US claimed
EP-4204100-A1 HAIR LIGHTENING COMPOSITIONS PROVIDING DAMAGE PROTECTION AND SENSORIAL BENEFITS AND METHODS OF USE L'OREAL (FR) 2023-07-05 EP disclosed
US-11559474-B2 Hair lightening compositions and methods of use L'OREAL (FR) 2023-01-24 US disclosed
WO-2022047081-A1 HAIR LIGHTENING COMPOSITIONS PROVIDING DAMAGE PROTECTION AND SENSORIAL BENEFITS AND METHODS OF USE HENRY DEREK (US) 2022-03-03 WO disclosed
WO-2018119500-A1 VISCOELASTIC COSMETIC COMPOSITIONS L'OREAL (FR) 2018-07-05 WO disclosed
US-8968711-B2 Cosmetic or dermatological composition comprising a polymer bearing junction groups, and cosmetic treatment process L'OREAL (FR) 2015-03-03 US disclosed
US-20100272660-A1 COSMETIC OR PHARMACEUTICAL COMPOSITION COMPRISING A POLYCONDENSATE, THE SAID POLYCONDENSATE AND METHOD OF COSMETIC TREATMENT L'OREAL (FR) 2010-10-28 US disclosed
US-20100239509-A1 COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A POLYMER BEARING JUNCTION GROUPS, AND COSMETIC TREATMENT PROCESS L'OREAL (FR) 2010-09-23 US disclosed
US-20090028807-A1 COMPOSITION COMPRISING A POLYCONDENSATE, METHOD OF TREATMENT, POLYCONDENSATE, AND METHOD OF PREPARATION L'OREAL (FR) 2009-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100239509-A1 COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A POLYMER BEARING JUNCTION GROUPS, AND COSMETIC TREATMENT PROCESS CUTA, SUCLG1, KRT18 PRMT1 4663/4885CASP2 3681/4885ADRA1A 4844/4885
US-20090028807-A1 COMPOSITION COMPRISING A POLYCONDENSATE, METHOD OF TREATMENT, POLYCONDENSATE, AND METHOD OF PREPARATION CUTA, SYMPK, TPRKB PRMT1 2654/4885CASP2 3763/4885ADRA1A 4879/4885
US-20100272660-A1 COSMETIC OR PHARMACEUTICAL COMPOSITION COMPRISING A POLYCONDENSATE, THE SAID POLYCONDENSATE AND METHOD OF COSMETIC TREATMENT ACMSD, CUTA, PCCA PRMT1 2072/4885CASP2 1878/4885ADRA1A 4380/4885
US-11559474-B2 Hair lightening compositions and methods of use TYR, ALAD, CYBA PRMT1 1066/4885CASP2 3656/4885ADRA1A 4779/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.